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This editorial refers to ‘Geranylgeranyl pyrophosphate syn-
thase facilitates the organization of cardiomyocytes during
mid-gestation through modulating protein geranylgeranyla-
tion inmouse heart’ by Z. Chen et al., pp. 965–978.
The morphogenesis of the myocardial wall is a complex process and dis-
ruption can lead to congenital heart disease (CHD). Thus, identifying
genes and intracellular processes that are essential for heart develop-
ment will provide pivotal genetic information for the management of
CHD. The exact details of how the cardiomyocytes assemble and inter-
act to form the correct myocardial mass and dimensions are still part of
ongoing research in many laboratories. In this issue of Cardiovascular
Research, Chen et al.1 introduces the novel idea that the process of pro-
tein geranylgeranylation is required for the arrangement of early cardio-
myocytes during ventricular chamber maturation.
Protein geranylgeranylation is a form of prenylation and is an essential
type of post-translational modification of proteins. It involves the attach-
ment of lipophilic geranylgeranyl isoprene residues to a cysteine located
at the C-terminus of specific proteins. This subsequently acts as a mem-
brane anchor for the modified target protein, triggering the translocation
of the protein from the cytosol to the membrane, hence activating the
protein. The mevalonate pathway regulates the process of geranylgera-
nylation. It leads to the production of farnesyl pyrophosphate (FPP),
which is synthesized into geranylgeranyl pyrophosphate (GGPP) by the
enzyme, geranylgeranyl pyrophosphate synthase (Ggpps). Downstream,
the enzyme, geranylgeranyl transferase I (GGTase I), then catalyses the
addition of one geranylgeranyl group from GGPP onto the target
protein.
The heart initially consists of a single layer of cardiomyocytes, which
mature and proliferate under the control of many different genetic path-
ways, to form thick compact myocardium and trabeculae layers. Early
embryonic cardiomyocytes are polygonal in shape with the cell–cell
junctions arranged uniformly around the cell membrane.2 The adherens
junctions are the major anchorage sites for actin cytoskeleton, the myofi-
brils, which initially run in random orientations during embryonic devel-
opment. Disruption of cellular junctions early in development leads to
heart defects and embryonic lethality. During trabeculae formation, tra-
becular cardiomyocytes undergo directional migration or orientation
cell division, forming new cell–cell junctions. Adherens junctions are
required to establish both of these processes as loss of N-cadherin led
to trabeculation defects.3 Hence, the integrity of cell-cell junctions are
essential to maintain the rigidity of the cytoarchitecture required for de-
velopment of the ventricular wall.
This is the first publication to study specifically the role of Ggpps in the
developing mammalian heart. Previous publications showed that
enzymes involved in the mevalonate pathway, including GGPPS, in
Drosophila and zebrafish, control the early stages of heart formation.4,5
Chen et al. have previously published the deletion of Ggpps in postnatal
cardiomyocytes. These mutant mice developed heart failure and died at
2months, highlighting the role of Ggpps in controlling postnatal heart
growth by regulating cardiomyocyte cell size.6 These studies did not
identify the target substrate that required geranylgeranylation, but al-
luded to the possibility that the Rho family members are involved. Links
between decreased GGPP levels and reduced RhoA activation have
been reported in adult rat hearts.7
The authors used two Cre lines, Nkx2.5-Cre and a-SMA-Cre, to delete
Ggpps, leading to disruption of protein geranylgeranylation at E9.5 and
E13.5, respectively. Disruption of protein geranylgeranylation, in the for-
mer, affected ventricular chamber maturation and caused embryonic le-
thality between E12.0 and E13.0, whereas later disruption of the process
using the a-SMA-Cre line had no effect on the phenotype. The organiza-
tion of the cytoskeleton was affected, as abnormal sarcomeres were pre-
sent and proteins associated with the adherens and gap junctions in the
ventricular wall were disrupted at E11.5; they attributed this to specific
reduction of geranylgeranylation of Rho GTPases, RhoA, and Rac1. The
abnormal cytoarchitecture of the cardiomyocytes coincided with re-
duced proliferation, hence accounting for the thin myocardium.
However, the direct link between geranylgeranylation of Rho GTPases,
cell junction maintenance and proliferation is still unclear.
As Nkx2.5-Cre is expressed in cardiomyocytes, smooth muscle, and
endothelial lineages of the developing heart8 the cell specificity of protein
geranylgeranylation could be further addressed by using alternative
transgenic mouse Cre lines to target individual cell populations, for ex-
ample TnT-Cre (cardiomyocytes only).
The authors, focused on RhoA and Rac1 as downstream targets of
geranylgeranylation, and proved by western blot analysis that there was
reduced membrane bound and prenylated forms of each of these
proteins, without a reduction in total protein. Further dual staining, could
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Figure 1 Potential role of protein geranylgeranylation in the maturation of the ventricular wall. The mevalonate pathway leads to protein geranylgeranyla-
tion of downstream targets. In normal heart development the enzyme, Ggpps, converts FPP into GGPP, from which a geranylgeranyl group is transferred by
GGTase I, to activate members of the RhoGTPase family. The membrane bound RhoGTPases are required for proliferation, and the maintenance of the
cell–cell junctions and the actin cytoskeleton, hence establishing the polygonal shape of embryonic cardiomyocytes, and subsequent maturation of the ven-
tricular wall (A). Deletion of Ggpps reduces the activity of RhoA and Rac1, and potentially further members of the RhoGTPase family, through decreased
geranylgeranylation at E9.5; possibly leading to an increase in cytoplasmic localisation of RhoGTPases. Loss of cell junction and actin cytoskeleton integrity
alters the cell shape of the cardiomyocytes, leading to a visually abnormal cytoarchitecture of the ventricular wall at E11.5, and subsequent embryonic death
a day later. Deletion of Cdc42 was reported to lead to a very similar phenotype12 highlighting the importance of active RhoGTPases in early heart develop-
ment (B). FPPS, farnesyl pyrophosphate synthase; FPP, farnesyl pyrophosphate; Ggpps, geranylgeranyl pyrophosphate synthase; GGPP, geranylgeranyl pyro-
phosphate; GGTase I, geranylgeranyl transferase I.
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..establish if the altered cellular distribution of RhoA and Rac1 is located in
the endocardial, cardiomyocytes and/or epicardial cell lineages. They
confirmed that this reduction in geranylgeranylation of RhoA and Rac1
led to reduced levels of active GTP-bound form of each protein.
Chemical administration of GGPP in vitro and in vivo (via GGOH) rescued
the phenotype, but the authors did not show that this specifically in-
creased geranylgeranylation of RhoA and Rac1.
Another enzyme in the mevalonate pathway is farnesyl pyrophos-
phate synthase (FPPS), which is required for the production of FPP. As
described, FFP can be converted into GGPP or directly leads to another
type of protein prenylation, farnesylation. In their previous publication,
the deletion of Ggpps in postnatal hearts, led to increased farnesylation
as a consequence of decreased geranylgeranylation6 and overexpression
of FPPS is a known regulator of myocardial remodeling.9 However, the
level of farnesylation was not addressed in the current publication and
may be involved in heart development.
This study is the first to implicate that the geranylgeranylation of
RhoA and Rac1 is essential for cardiomyocyte integrity and hence ven-
tricular development, and opens up a number of questions. Both of these
Rho GTPases have a number of downstream targets and establishing,
which are affected by the reduced geranylgeranylation, would generate a
mechanism of the exact cause of the heart defects described.
Furthermore, as there are over 22 members of the Rho GTPase family,
the deletion of Ggpps may impact on these through altered geranylgera-
nylation or farnesylation.10 For example, the activity of Cdc42 is depen-
dent upon prenylation11 and is essential for the establishment of
adherens junctions. Embryonic deletion of Cdc42 in cardiomyocytes,
caused embryonic lethality after E12.5 with heart defects including thin
ventricle walls, which the authors attributed to reduced cardiomyocyte
proliferation and impaired formation of adherens junction cell–cell con-
tacts,12 thus presenting a similar phenotype as described in this article by
Chen et al. Therefore, this opens up the possibility that the geranylgera-
nylation of Cdc42 may be altered in the Nkx2.5Cre/þ; Ggppsfl/fl mutants as
well. How exactly these RhoGTPases control adhesion between cardio-
myocytes remains elusive, but the level of protein geranylgeranylation of
other members of this family is worth pursuing.
In conclusion, Chen et al., have introduced the idea that protein gera-
nylgeranylation is an important step during cardiomyocyte maturation
and is required for the maintenance of cellular junctions. This raises the
possibility that other components upstream and downstream in the
mevalonate pathway and other members of the Rho GTPase family may
be potential disease causing genes in CHD (Figure 1) .
Conflict of interest: none declared.
References
1. Chen Z, Xu Chong N, Guan D, Jiang S, Yang CZ, Li C. Geranylgeranyl pyrophos-
phate synthase facilitates the organization of cardiomyocytes during mid-gestation
through modulating protein geranylgeranylation in mouse heart. Cardiovasc Res 2018;
114:965–978.
2. Hirschy A, Schatzmann F, Ehler E, Perriard JC. Establishment of cardiac cytoarchitec-
ture in the developing mouse heart. Dev Biol 2006;289:430–441.
3. Li J, Miao L, Shieh D, Spiotto E, Li J, Zhou B, Paul A, Schwartz RJ, Firulli AB, Singer HA,
Huang G, Wu M. Single-cell lineage tracing reveals that oriented cell division contrib-
utes to trabecular morphogenesis and regional specification. Cell Rep 2016;15:158–170.
4. Yi P, Han Z, Li X, Olson EN. The mevalonate pathway controls heart formation in
Drosophila by isoprenylation of Ggamma1. Science 2006;313:1301–1303.
5. D’Amico L, Scott IC, Jungblut B, Stainier DY. A mutation in zebrafish hmgcr1b
reveals a role for isoprenoids in vertebrate heart-tube formation. Curr Biol 2007;17:
252–259.
6. Xu N, Guan S, Chen Z, Yu Y, Xie J, Pan FY, Zhao NW, Liu L, Yang ZZ, Gao X, Xu
B, Li CJ. The alteration of protein prenylation induces cardiomyocyte hypertrophy
through Rheb-mTORC1 signalling and leads to chronic heart failure. J Pathol 2015;
235:672–685.
7. Yang J, Chen YN, Xu ZX, Mou Y, Zheng LR. Alteration of RhoA prenylation amelio-
rates cardiac and vascular remodeling in spontaneously hypertensive rats. Cell Physiol
Biochem 2016;39:229–241.
8. Ma Q, Zhou B, Pu WT. Reassessment of Isl1 and Nkx2-5 cardiac fate maps using a
Gata4-based reporter of Cre activity. Dev Biol 2008;323:98–104.
9. Yang J, Mou Y, Wu T, Ye Y, Jiang JC, Zhao CZ, Zhu HH, Du CQ, Zhou L, Hu SJ.
Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac
hypertrophy and dysfunction in mice. Cardiovasc Res 2013;97:490–499.
10. Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, Cox AD, Wilson O,
Kirschmeier P, Der CJ. Rho Family GTPase modification and dependence on CAAX
motif-signaled posttranslational modification. J Biol Chem 2008;283:25150–25163.
11. Zhou Y, Johnson JL, Cerione RA, Erickson JW. Prenylation and membrane localization
of Cdc42 are essential for activation by DOCK7. Biochemistry 2013;52:4354–4363.
12. Li J, Liu Y, Jin Y, Wang R, Wang J, Lu S, VanBuren V, Dostal DE, Zhang SL, Peng X.
Essential role of Cdc42 in cardiomyocyte proliferation and cell-cell adhesion during
heart development. Dev Biol 2017;421:271–283.
924 Editorial
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article-abstract/114/7/922/4976584 by U
niversity of N
ew
castle user on 23 M
ay 2019
